Keyphrases
Ovarian Cancer
100%
Therapeutic Target
100%
Clinical Strategies
100%
Ovarian Cancer Cells
80%
BI6727
80%
Small Interfering RNA (siRNA)
60%
MK-1775
60%
Molecular Targets
40%
Conventional Chemotherapy
40%
Lapatinib
40%
Lethality
40%
Co-treatment
40%
Pharmacological Inhibitors
40%
Short Hairpin RNA (shRNA)
40%
Cytotoxic Effect
40%
Lethal Concentration
40%
RNAi Screen
40%
High-throughput
20%
Clinically Significant
20%
In Cancer
20%
Tumor
20%
Loss Function
20%
Cisplatin
20%
Treatment Strategy
20%
Therapeutic Strategies
20%
Cancer Biology
20%
Chemical Inhibitors
20%
ErbB2
20%
Related Pathway
20%
Nuclear factor-κB
20%
Therapeutic Potential
20%
Dysregulated
20%
Advanced Stage
20%
Overall Survival
20%
Clinical Significance
20%
Polo-like Kinase 1 (PLK1)
20%
Statistical Significance
20%
Sequential Exposure
20%
Stage at Diagnosis
20%
Extended Period
20%
Regrowth
20%
Viability Assay
20%
Cellular Viability
20%
Cytostatic
20%
Cancer Genome Atlas
20%
High Response Rate
20%
WEE1
20%
2-way
20%
Cancer Dataset
20%
TAK1
20%
Simultaneous Exposure
20%
Essential Targets
20%
Target Validation
20%
Co-inhibition
20%
MAP3K7
20%
Loss-of-function Screen
20%
Cytotoxic Concentration
20%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Small Hairpin RNA
100%
Small Interfering RNA
75%
Lapatinib
50%
Cytotoxicity
50%
Candidate Gene
25%
PLK1
25%
MAP3K7
25%
Cisplatin
25%
Overall Survival
25%
Sensitization
25%
Cell Viability
25%
Cytotoxic Concentration
25%
Medicine and Dentistry
Ovarian Cancer
100%
Short Hairpin RNA
50%
Volasertib
50%
Cancer Cell
37%
Small Interfering RNA
37%
Adavosertib
37%
Lethality
25%
The Cancer Genome Atlas
25%
Cytotoxicity
25%
Lapatinib
25%
In Vitro
12%
Neoplasm
12%
Cancer Pathobiology
12%
Minoxidil
12%
Sensitization
12%
Overall Survival
12%
Cell Viability
12%
Ovarian Cancer Cell Line
12%
Cytostatic Agent
12%
Cytotoxic Agent
12%
Cisplatin
12%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Short Hairpin RNA
44%
Volasertib
44%
Small Interfering RNA
33%
Adavosertib
33%
Chemotherapy
22%
Molecular Target
22%
Lapatinib
22%
Malignant Neoplasm
22%
Lethality
22%
Cisplatin
11%
Viability Assay
11%
Overall Survival
11%
Cytotoxic Agent
11%
Cytostatic Agent
11%
Neoplasm
11%
Minoxidil
11%